I got the impression that the article was generally anti-patents and I framed my response in that context. A ban on patents has been beneficial for the generics industry but if it has a higher cost in terms of stifling novel therapeutics, which also have a benefit, then it may be an overall loss for the population as a whole. In this way there is little difference between a ban on patents being good for the generics industry and strong copyright laws being good for the record industry. Both may be true but the interests of the population may not be aligned perfectly with these industries.
On the other hand if research into novel therapeutics is able to thrive with a ban on patents then you get the benefits of new therapies and the affordable prices. This is what I would like to see before dismissing the patent system entirely when what may be best is a little tweaking.
Finally on marketing versus R&D I'm not sure that the multiple could genuinely said to be 'very large.' This article suggests marketing:R&D is 2:1. http://www.plosmedicine.org/article/info:doi/10.1371/journal...